The Risk of Hepatocellular Carcinoma After Directly Acting Antivirals for Hepatitis C Virus Treatment in Liver Transplanted Patients: Is It Real?

Alessio Strazzulla,1* Rosa Maria Rita Iemmolo,2 Ennio Carbone,3,4 Maria Concetta Postorino,1 Maria Mazzitelli,1 Mario De Santis,5 Fabrizio Di Benedetto,2 Costanza Maria Cristiani,3 Chiara Costa,1 Vincenzo Pisani,1 and Carlo Torti1

1Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, “Magna Graecia” University, Catanzaro, Italy
2Liver and Multivisceral Transplant Center, University of Modena and Reggio Emilia, Modena, Italy
3Experimental and Clinic Medicine, Department of Experimental and Clinical Medicine, “Magna Graecia” University, Catanzaro, Italy
4Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden
5Unit of Radiology, University of Modena and Reggio Emilia, Modena, Italy

*Corresponding author: Alessio Strazzulla, Unit of Infectious and Tropical Diseases, Department of Medical and Surgical Sciences, "Magna Graecia" University, Viale Europa, 1, 88100 Catanzaro, Italy. E-mail: alessiostrazzulla@yahoo.it

Received 2016 August 31; Revised 2016 October 07; Accepted 2016 October 17.

Abstract

Introduction: Since directly acting antivirals (DAAs) for treatment of hepatitis C virus (HCV) were introduced, conflicting data emerged about the risk of hepatocellular carcinoma (HCC) after interferon (IFN)-free treatments. We present a case of recurrent, extra-hepatic HCC in a liver-transplanted patient soon after successful treatment with DAAs, along with a short review of literature.

Case Presentation: In 2010, a 53-year-old man, affected by chronic HCV (genotype 1) infection and decompensated cirrhosis, underwent liver resection for HCC and subsequently received orthotopic liver transplantation. Then, HCV relapsed and, in 2013, he was treated with pegylated-IFN plus ribavirin; but response was null. In 2014, he was treated with daclatasvir plus simeprevir to reach sustained virological response. At baseline and at the end of HCV treatment, computed tomography (CT) scan of abdomen excluded any lesions suspected for HCC. However, alpha-fetoprotein was 2.9 ng/mL before DAAs, increasing up to 183.1 ng/mL at week-24 of follow-up after the completion of therapy. Therefore, CT scan of abdomen was performed again, showing two splenic HCC lesions.

Conclusions: Overall, nine studies have been published about the risk of HCC after DAAs. Patients with previous HCC should be carefully investigated to confirm complete HCC remission before starting, and proactive follow-up should be performed after DAA treatment.

Keywords: Directly Acting Antivirals, Hepatocellular Carcinoma, Hepatitis C Virus, Interferon, Liver Transplant

1. Introduction

During the interferon (IFN) era of chronic hepatitis C treatment, it was almost unanimously accepted that sustained virologic response (SVR) provides reduction of hepatocellular carcinoma (HCC), even though mortality due to HCC still remained almost 25-fold higher in patients who eradicated hepatitis C virus (HCV) than in HCV negative people (1, 2). With the advent of directly acting antivirals (DAAs), some conflicting data have emerged about an increased risk of HCC after IFN-free treatments, provoking a huge debate among the scientific community (3, 4). More specifically, some authors found unexpected high rates of de-novo or recurrent HCC after DAA treatment whereas other authors did not find any significant risk (5, 6). A similar dichotomy affected also data about risk of HCC after DAAs in liver transplanted patients (7, 8).

We aimed at contributing to the debate with presenting a case of recurrent, extra-hepatic HCC in a liver-transplanted patient soon after successful treatment with DAAs. Furthermore, we provide a short review of all cohort studies or case series that evaluated incidence of HCC after DAA treatment in the IFN-free era.

2. Case Presentation

In 2010, a 53-year-old diabetic man, affected by chronic HCV (genotype 1) infection and decompensated liver cirrhosis, underwent liver resection for HCC (already treated...
with successful transarterial-chemoembolization) and received subsequently a liver transplant from a HBcAb-positive donor. Importantly, at time of transplant, no residual foci of HCC were present. Then, HCV relapsed and, in 2013, a liver biopsy showed overall inflammation grade 6 and fibrosis stage 1 (Ishak’s classification). In the same year, he was treated with pegylated-IFN plus ribavirin; but response was null. In 2014, he was treated with daclatasvir plus simeprevir as part of an expanded access program (9) for 24 weeks to reach SVR. At baseline and at the end of HCV treatment, the patient underwent computed tomography (CT) scan of abdomen, which excluded any suspected lesions. However, alpha-fetoprotein that was 2.9 ng/mL before DAA increased up to 183.1 ng/mL at week-24 of follow-up since ending DAA. Therefore, CT scan of abdomen was repeated, showing two splenic lesions suggestive for HCC (Figure 1). Sorafenib was initiated. This treatment is still ongoing at time of paper submission.

Figure 1. Contrast Enhanced Computed Tomography of Abdomen

The image shows two solid-vascularized lesions of circa 2 × 2 cm at the splenic hilum and posterior extremity of the spleen. The two grey arrows indicate the two malignant lesions.

3. Discussion

This case provoked our interest and, for this reason, we updated our knowledge by reviewing all cohort studies or case series, which evaluated the risk of development of HCC in patients treated with IFN-free regimens published from January 1st, 2016 to August 15th, 2016.

Overall, we reviewed nine published or accepted articles (Table 1) (5-8, 10-14). It is difficult to find consistent data about the incidence of HCC after HCV treatment because these studies have different inclusion criteria and designs. There are also intrinsic limitations. Moreover, it is possible that some patients received DAAs too early after treatment for HCC, so, at least in some cases, HCC was already present before DAAs but not detected because of limitations in the resolution of imaging techniques. For the same reason, we cannot exclude, also in our case, the possibility that HCC was still growing in the time frame between transplant and HCV treatment but its size was too small to be detected by CT scan. However, since liver transplant occurred five years before HCC recurrence and HCC recurrence happened soon after HCV virological response, the role of DAA treatment in promoting proliferation of neoplastic cells may be hypothesized.

Only two cohort studies have evaluated the risk of HCC in patients who received liver transplant, showing inconsistent results. Yang JD et al. (7) found that, among patients who received DAA treatment before liver transplant, HCC recurrences were more frequent than in transplanted patients who did not receive HCV therapy [5/18 (27.5%) vs. 6/63 (9.5%), P = 0.06]. Moreover, early HCC recurrences (i.e., within 6 months of liver transplant) occurred more frequently among DAA-treated than non-treated patients [4/5 (80%) vs. 2/6 (33%)]. Notably, all DAA-treated patients with HCC recurrence had extra-hepatic lesions, which is consistent with what happened in our case. By contrast, data on transplanted patients from a French cohort (8), showed an incidence of HCC recurrence in only 2.2% cases (7/314) when DAA treatment was prescribed. Differences in the sample size and characteristics of the patient population and treatment strategy (DAA prescribed before or after liver transplant) may explain this apparent discrepancy.

Although the risk of HCC after DAA is of great concern because it may suggest a pro-oncogenic role of DAAs (15), it is somehow reassuring to see that this risk is mainly affecting patients with a previous HCC. Indeed, Cheung MCM et al. (5) found that 2/29 (6.8%) patients with previous HCC had recurrences while 15/377 (3.9%) patients without previous history of HCC had primary HCC diagnosis. Similarly, Conti et al. found that 17/59 (28.8%) patients had HCC recurrences while 9/285 (3.16%) patients had a primary HCC diagnosis (13).

To explain why some people develop HCC after DAA treatment, only speculative hypotheses can be made. One is that DAAs cause a deregulation of immune-system through an abrupt reduction in the HCV load, leaving immune-cells less active against tumor cells already present at the beginning of antiviral treatment. In fact, HCV infection leads to IFN production that is able to directly eliminate neoplastic clones through a modulation of the inflammatory milieu and activate natural killer cell/cytotoxic T lymphocytes mediated cytotoxicity (1, 2). This scenario suggests that HCV infection works as “adjuvant” for anti-cancer immune response. Moreover, during treatment with DAAs, the immune cell-dysfunction per-
exists also after successful HCV treatment with IFN-free regimens (16).

For the same reasons, it may be hypothesized that, while exogenous IFN used as part of HCV treatment plays a protective role in HCC because it “switches-on” inflammatory cells with pro-apoptotic and anti-tumoral activities (17), IFN-free treatments eradicate HCV more easily but neoplastic clones continue to replicate in a setting of reduced inflammation because DAAs eliminate HCV from cells without cleaning them out. In our case, IFN-based treatment prescribed in 2013, could have delayed HCC recurrence. Thus, we speculate that a “tail” of IFN after HCV eradication might reduce the risk of recurrent or de-novo HCC. This possible biphasic trend in the risk (i.e., greater soon after HCV eradication, lowering afterwards as HCV damage and fibrosis restore) is consistent with immune-reconstitution phenomenon in other infectious diseases, such as immune reconstitution inflammatory syndrome during infection by human immunodeficiency virus (20). It could be interesting to see whether IFN administration (concomitant to DAA or as a tail after SVR) confers protection against HCC recurrence.

In conclusion, in the meantime, while it is not reasonable to delay HCV treatment, residual HCC should be excluded with sensitive methods and a pro-active follow-up should be applied.

Acknowledgments

None.

Footnotes

Authors’ Contribution: Alessio Strazzulla drafted the manuscript; Rosa Maria Rita Iemmolo participated...
in reviewing the manuscript; Ennio Carbone drafted the manuscript; Maria Concetta Postorino drafted the manuscript; Maria Mazzitelli participated in reviewing the manuscript; Mario De Santis involved in data collection (imaging); Fabrizio Di Benedetto involved in data collection (imaging), Costanza Maria Cristiani drafted the manuscript; Chiara Costa participated in reviewing the manuscript, Vincenzo Pisani participated in reviewing the manuscript; Carlo Torti drafted the manuscript and participated in reviewing the manuscript.

**Financial Disclosure:** All authors declare that they have not any support from any organization for the submitted work. Also, there is no financial relationship with any organization that might have an interest in the submitted work or non-profit sectors.

**References**

1. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. *Ann Oncol.* 2016;27(8):1467-74. doi: 10.1093/annonc/mdw219. [PubMed: 27226385].

2. Innes H, McDonald S, Hayes P, Dillon JF, Allen S, Goldberg D, et al. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population. *J Hepatol.* 2016. doi: 10.1016/j.jhep.2016.08.004. [PubMed: 2754496].

3. Nault JC, Colombo M. Hepatocellular carcinoma and direct acting antiviral treatments: Controversy after the revolution. *J Hepatol.* 2016;65(4):663-5. doi: 10.1016/j.jhep.2016.07.004. [PubMed: 27471726].

4. Camma C, Cabibbo G, Craxi A. Direct antiviral agents and risk for HCC early recurrence: Much ado about nothing. *J Hepatol.* 2016;65(4):385-2. doi: 10.1016/j.jhep.2016.04.033. [PubMed: 27255578].

5. Cheung MC, Walker AJ, Hudson BE, Verma S, McLaughlin J, Mutimer DJ, et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. *J Hepatol.* 2016;65(4):741-7. doi: 10.1016/j.jhep.2016.06.009. [PubMed: 27388925].

6. Reig M, Marino Z, Perello C, Iñarraírategui M, Ribeiro A, Lens S, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. *J Hepatol.* 2016.

7. Yang JD, Aqil BA, Pungpapong S, Gores GJ, Roberts JR, Leise MD. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcinoma. *J Hepatol.* 2016;65(4):859-60. doi: 10.1016/j.jhep.2016.06.023. [PubMed: 27392425].

8. ANRS collaborative study group on hepatocellular carcinoma [ANRS C022 HEPATITIS CCACC]. Lack of evidence of an effect of Direct Acting Antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. *J Hepatol.* 2016.

9. Fontana RJ, Brown RS, Moreno-Zamora A, Prieto M, Joshi S, Londono MC, et al. Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. *Liver Transpl.* 2016;22(4):446-58. doi: 10.1002/lt.24416. [PubMed: 26890629].

10. Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. *J Hepatol.* 2016;65(4):856-8. doi: 10.1016/j.jhep.2016.06.009. [PubMed: 27383272].

11. Cardoso H, Vale AM, Rodrigues S, Goncalves R, Albuquerque A, Pereira P, et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis. *J Hepatol.* 2016;65(5):1070-1. doi: 10.1016/j.jhep.2016.07.027. [PubMed: 27476788].

12. Minami T, Tateishi R, Nakagomi R, Fujisawa N, Sato M, Enooku K, et al. The impact of direct-acting antivirals on early tumor recurrence after radiofrequency ablation in hepatitis C-related hepatocellular carcinoma. *J Hepatol.* 2016 doi: 10.1016/j.jhep.2016.07.043. [PubMed: 27524465].

13. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. *J Hepatol.* 2016;65(4):727-33. doi: 10.1016/j.jhep.2016.06.015. [PubMed: 27349488].

14. Kobayashi M, Suzuki F, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. *J Med Virol.* 2016;88(10):581-2. doi: 10.1002/jmv.24663. [PubMed: 27535186].

15. Llovet JM, Villanueva A. Liver cancer: Effect of HCV clearance with direct-acting antiviral agents on HCC. *Nat Rev Gastroenterol Hepatol.* 2016;13(10):561-2. doi: 10.1038/nrgastro.2016.140. [PubMed: 27508683].

16. Goossens N, Hoshida Y. Hepatitis C virus-induced hepatocellular carcinoma. *Clin Mol Hepatol.* 2015;21(2):105-14. doi: 10.3550/cmh.2015.21.2.105. [PubMed: 26517746].

17. Hengst J, Strunz B, Deterdong K, Jünggren HG, Leesawy E, Manns MP, et al. Nonreversible MAIT cell-dysfunction in chronic hepatitis C virus infection despite successful interferon-free therapy. *Eur J Immunol.* 2016;46(9):2204-10. doi: 10.1002/eji.201646447. [PubMed: 27296288].

18. Serti E, Park H, Keame M, O’Keefe AC, Rivera E, Liang TJ, et al. Rapid decrease in hepatitis C viremia by direct acting antivirals improves the natural killer cell response to IFNα/β. *Gut.* 2016. doi: 10.1136/gutjnl-2015-300333. [PubMed: 26733670].

19. European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. *Liver Transpl.* 2016;22(4):908-43. doi: 10.1002/lt.24416. [PubMed: 22424438].

20. Walker NF, Scriven J, McIntjes G, Wilkinson RJ. Immune reconstitution inflammatory syndrome in HIV-infected patients. *HIV AIDS (Auckl).* 2015;7:49-64. doi: 10.2147/HIVS42328. [PubMed: 25709503].

**Funding/Support:** This study did not receive specific grant from any funding agency in the public, commercial or non-profit sectors.